Drug Discovery


Continued from page 37


21 Polo, JM, Liu, S, Figueroa, ME, Kulalert, W, Eminli, S, Tan, KY, Apostolou, E, Stadtfeld, M, Li, Y, Shioda, T, Natesan, S, Wagers, AJ, Melnick, A, Evans, T and Hochedlinger, K. (2010). Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 28 (8):848-55. 22 Kehat, I, Kenyagin-Karsenti, D, Snir, M, Segev, H, Amit, M, Gepstein, A, Livne, E, Binah, O, Itskovitz-Eldor, J and Gepstein, L. (2001). Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 108 (3):407-14. 23 He, JQ, Ma, Y, Lee, Y, Thomson, JA and Kamp, TJ. (2003). Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 93(1):32-9. 24 Sullivan, GJ, Hay, DC, Park, IH, Fletcher, J, Hannoun, Z, Payne, CM, Dalgetty, D, Black, JR, Ross, JA, Samuel, K, Wang, G, Daley, GQ, Lee, JH, Church, GM, Forbes, SJ, Iredale, JP and Wilmut, I. (2010). Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 51(1):329-35. 25 Kola, I and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rate? Nat Rev Drug Dis 3:711-6. 26 Gwathmey, JK, Tsaioun, K and Hajjar, RJ. (2009). Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates. Expert Opin. Drug Metab. Toxicol 5(6):647-60. 27 Peng, S, Lacerda, AE, Kirsch, GE, Brown, AM and Bruening-Wright, A. (2010). The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J Pharmacol Toxicol Methods 61(3):277-86. 28 Donato, MT, Lahoz, A, Castell, JV and Gómez-Lechón, MJ. (2008). Cell Lines: A tool for In Vitro Drug Metabolism Studies. Curr Drug Metab 9:1-11. 29 Sancho-Bru, P, Roelandt, P, Narain, N, Pauwelyn, K, Notelaers, T, Shimizu, T, Ott, M and Verfaillie, C. (2010). Directed differentiation of murine-induced pluripotent stem cells to functional hepatocyte-like cells. J Hepatology, 54(1): 98-107 30 Guguen-Guillouzo, C, Corlu, A, Guillouzo, A. (2010). Stem cell-derived heptocytes and their use in toxicology. Toxicology 270:3-9. 31 McNeish, J, Roach, M, Hambor, J, Mather, RJ, Weibley, L, Lazzaro, J, Gazard, J, Schwarz, J, Volkmann, R, Machacek, D, Zawadzke, L, O’Donnell, C and Hurst, R. (2010). High- throughput screening in embryonic stem cell- derived neurons identifies potentiators of a- amino-3-hydroxyl-5-methyl-4- isoxazolepropionate-type glutamate receptors. J Biol. Chem. 285(22):17209-17. 32 Ebert, AD, Yu, J, Rose, FF, Mattis, VB, Lorson, CL, Thomson, JA and Svendsen, CN. (2009). Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457:277-81.


38


33 Lee, G, Papapetrou, EP, Kim, H, Chambers, SM, Tomishima, MJ, Fasano, CA, Ganat, YM, Menon, J, Shimizu, F, Viale, A, Tabar, V Sadelain, M, and Studer L. (2009). Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461(7262):402-6. 34 Chan, AWS, Cheng, P-H, Neumann, A and Yang, J-J. Reprogramming Huntington monkey skin cells into pluripotent stem cells. (2010). Cellular Reprogramming 12(5):509-17. 35 Moretti, A, Bellin, M, Welling, A, Jung, CB, Lam, JT, Bott-Flügel, L, Dorn, T, Goedel, A, Höhnke, C, Hofmann, F, Seyfarth, M, Sinnecker, D, Schömig, A and Laugwitz, KL. (2010). Patient-specific induced pluripotent stem-cell models for long- QT syndrome. N Engl J Med 363(15):1397-409. 36 Carvajal-Vergara, X, Sevilla, A, D'Souza, SL, Ang, YS, Schaniel, C, Lee, DF, Yang, L, Kaplan, AD, Adler, ED, Rozov, R, Ge, Y, Cohen, N, Edelmann, LJ, Chang, B, Waghray, A, Su, J, Pardo, S, Lichtenbelt, KD, Tartaglia, M, Gelb, BD and Lemischka, IR. (2010). Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465(7299):808-12. 37 Raval, KK, Koonce, CH, Zhang, J, Yu, J, Kamp, TJ and Thomson, JA. (2010). A Human Induced Pluripotent Stem Cell-derived Cardiomyocyte Model of Pompe Disease. Circulation 122: A19502. 38 Rashid, ST, Corbineau, S, Hannan, N, Marciniak, SJ, Miranda, E, Alexander, G, Huang- Doran, I, Griffin, J, Ahrlund-Richter, L, Skepper, J, Semple, R, Weber, A, Lomas, DA and Vallier, L. (2010). Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 120(9):3127-36. 39 Foldes, G, Mioulane, M, Wright, JS, Liu, AQ, Novak, P, Merkely, B, Gorelik, J, Schneider, MD, Ali, NN and Harding, SE. (2010). Modulation of human embryonic stem cell-derived cardiomyocyte growth: A testbed for studying human cardiac hypertrophy? J Mol Cell Cardiol, doi:10.1016/j.yjmcc.2010.10.029 40 Zhang, D, Jiang, W, Liu, M, Sui, X, Yin, X, Chen, S, Shi, Y and Deng, H. (2009). Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Research 19:429-38. 41 Borowiak, M and Melton DA. (2009). How to make  cells? Curr Opin Cell Biol. 21:727-32. 42 Kuzmenkin, A, Liang, H, Xu, G, Pfannkuche, K, Eichhorn, H, Fatima, A, Luo, H, Saric, T, Wernig, M, Jaenisch, R and Hescheler, J. (2009). Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro. FASEB, 23:4168-80. 43 Song, Z, Cai, J, Liu, Y, Zhao, D, Yong, J, Duo, S, Song, X, Guo, Y, Zhao, Y, Qin, H, Yin, X, Wu, C, Che, J, Lu, S, Ding, M and Deng, H. (2009). Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Research, 19(11):1233-42. 44 Hwang, D, Kim, DS and Kim, DW. (2010). Human ES and iPS cells as cell sources for the treatment of Parkinson’s disease: current state and problems. J Cell Biochem 109(2):292-301.


45 Parameswaran, S, Balasubramanian, S, Babai, N, Qiu, F, Eudy, JD, Thoreson, WB and Ahmad, I. (2010). Induced pluripotent stem cells generate both retinal ganglion cells and photoreceptors: Therapeutic implications in degenerative changes in glaucoma and age-related macular degeneration. Stem Cells 28:695-703. 46 Carr, A-J, Vugler, AA, Hikita, ST, Lawrence, JM, Gias, C, Chen, LL, Buchholz, DE, Ahmado, A, Semo, M, Smart, MJK, Hasan, S, da Cruz, L, Johnson, LV, Clegg, DO and PJ. (2009). Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. PLoS One 4(12):e0008512. 47 Espejel, S, Roll, GR, McLaughlin, KJ, Lee, AY, Zhang, JY, Laird, DJ, Okita, K, Yamanaka, S and Willenbring, H. (2010). Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest 120(9): 3120-6. 48 Alipio, Z, Liao, W, Roemer, EJ, Waner, M, Fink, LM, Ward, DC and Ward, Y. (2010). Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proc Natl Acad Sci USA 107(30):13426-31. 49 Lyssiotis, CA, Foreman, RK, Staerk, J, Garcia, M, Mathur, D, Markoulaki, S, Hanna, J, Lairson, LL, Charette, BD, Bouchez, LC, Bollong, M, Kunick, C, Brinker, A, Cho, CY, Schultz, PG and Jaenisch, R. (2009) Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A 106(22):8912-7. 50 Schneider, BL, Seehus, CR, Capowski, EE, Aebischer, P, Zhang, SC and Svendsen, CN. (2007). Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. Hum Mol Genet 16(6):651-66. 51 Agarwal, S, Loh, YH, McLoughlin, EM, Huang, J, Park, IH, Miller, JD, Huo, H, Okuka, M, Dos Reis, RM, Loewer, S, Ng, HH, Keefe, DL, Goldman, FD, Klingelhutz, AJ, Liu, L and Daley, GQ. (2010). Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 464(7286):292-6. Tolar, J, Park, IH, Xia, L, Lees, CJ, Peacock, B, Webber, B, McElmurry, RT, Eide, CR, Orchard, PJ, Kyba, M, Osborn, MJ, Lund, TC, Wagner, JE, Daley, GQ and Blazar, BR. (2010). Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood. Oct 29. doi:10.1182/blood-2010-05-287607. [Epub ahead of print].


Drug Discovery World Winter 2010/11


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80